ASCO 2025: Vepdegestrant Shows Superiority to Fulvestrant in ER+/HER2- Advanced Breast Cancer
Pharmacy Times
JUNE 9, 2025
months versus 2.1 months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois.
Let's personalize your content